GenoScreen’s Post

Did you know, our KASP™ assays are unmatched with 99.8% accuracy in calling the correct SNP genotype? Order your free KASP-TF trial kit here: https://hubs.li/Q02y-K_90 #genotyping #genotype #genomics

EIT Pathogena has a very ambitious goal to build a global pathogen surveillance network powered by direct-from-sample metagenomic testing.   Towards this goal, we’re developing user-friendly no-code pathogen genomics tools for species identification, antibiotic resistance prediction and genetic relatedness analysis. Our platform facilitates sharing of pathogen data within and between organisations, empowering users to detect and respond to outbreaks more effectively.   We’ve launched our first tool for Mycobacterium tuberculosis and non-tuberculous mycobacteria. Explore it here: https://lnkd.in/d3dUn2Fm   Don’t have mycobacterial genomic DNA samples? You can test the tool using publicly available samples from the European Nucleotide Archive (ENA): https://lnkd.in/dKFhqs_2

Ending TB by 2030 requires innovative tools like EIT Pathogena, a global pathogen surveillance network that enables early detection of cases and identification of drug-resistant strains. This tool has the potential to strengthen global health by enabling early outbreak detection, combating antimicrobial resistance, guiding resource allocation, and fostering collaboration to address both current and emerging health threats. #EndTB #AMR #pathogensurveillance #pandemicpreparedness

October is Gaucher disease awareness month! The incidence of Gaucher disease is estimated to be 1 in 50,000. It is associated with accumulation of lipids throughout the body. Revvity Omics’ offers the GBA #geneanalysis, which is associated with Gaucher disease. Reach out to know more about how we differentiate the pseudogene and perform the test on the true GBA genomic sequence. http://ms.spr.ly/6040mQN9e #RevvityOmics #raredisease #genomics #genetictesting

CYP2C19 #genotyping for patients undergoing treatment with mavacamten https://lnkd.in/dQph9Ntb #genomics #genomicmedicine #referral #genotyping

The global market for Targeted Sequencing and Resequencing was estimated to be worth US$ 45 million in 2023 and is forecast to a readjusted size of US$ 57 million by 2030 with a CAGR of 3.6% during the forecast period 20242030 #TargetedSequencing #Resequencing #Genomics #PersonalizedMedicine #ClinicalDiagnostics #DNASequencing #RNASequencing #GeneticResearch #HealthcareInnovation #GlobalMarket

In today’s episode of Genomics For All, Dr. Gautam Das, Ph.D. talks about the genomics for infectious diseases, particularly Tuberculosis. The drug resistance issue of tuberculosis has made it a very very difficult problem to tackle. If you want to know what we are doing at MiBiome Therapeutics to tackle this issue then watch the entire video! #genomicsforall #genes #genomesequencing #targetedNGS #tuberculosis #drugresistance #MiBiomeTherapeutics

RNA-Seq is critical for #CancerResearch & #DrugDevelopment research. Partner with our Services Team for confidence in your results, from consultation to publication-ready figures. ➡ https://bit.ly/46S0zmE #epigenetics #genomics #RNASeq #drugdiscovery

SMALL IS THE NEW BIG A new, compact targetted Next-Generation Sequencing (t-NGS) kit to detect multi-drug resistant tuberculosis Presented by @miBiome Friends, we ( scientists, clinicians, diagnostic labs, policy makers etc.) have been discussing the use of Next-Generation Sequencing in detection of tuberculosis Drug Resistance. Whole genome sequencing for detection of MDRTB has been attempted, but then why is a country like India with 25 lakh cases of TB per year unable to deploy this? Are cost-effective methods like t-NGS the way forward? Let's ask ourselves these practical questions and move ahead. Please view only "5 minutes of genomics" and have an independent view of using t-NGS for TB Drug resistance detection. Thanks for supporting #GFA and please stay tuned. Scientifically yours, Dr. Gautam Das, Ph.D. CEO and Co-Founder miBiome Therapeutics LLP

SORRY FOR THE SCARE....BUT THE NEXT PANDEMIC IN INDIA COULD BE MDR-TB COVID-19, apart from destroying life's and economies has taught us one thing: pandemic preparedness. It is the responsibility of everyone: Governments, Industry, Scientists, Clinicians, Hospitals, Diagnostic Labs and last but never the least: the COMMON MAN to get ourselves prepared for any adversity in Healthcare. Please watch "just 5 minutes of genomics" and let's all be ready to face the next possible pandemic developing slowly, right here in India: the TB drug resistance problem. Our solution: t-NGS for TB Drug Resistance, presented by @miBiome Thanks for supporting #GFA Please stay tuned for more updates. Scientifically yours, Dr. Gautam Das, Ph.D. CEO & Co-Founder miBiome Therapeutics LLP